MorphoSys Reports Positive Phase 3 Results for Myelofibrosis Drug Candidate (NASDAQ:MOR)
Bet_Noire/iStock via Getty Images MorphoSys(NASDAQ:MOR) said a Phase 3 study for its drug pelabresib met its primary endpoint in treating ...
Bet_Noire/iStock via Getty Images MorphoSys(NASDAQ:MOR) said a Phase 3 study for its drug pelabresib met its primary endpoint in treating ...